ICD-10 Coding for Transitional Cell Carcinoma(C67.0, C67.2, C67.2B)
Learn about the ICD-10 coding for transitional cell carcinoma, including documentation requirements and common pitfalls. Ensure accurate billing and compliance with updated terminology.
Complete code families applicable to Transitional Cell Carcinoma
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C67.2 | Malignant neoplasm of lateral wall of bladder | Use when pathology confirms TCC on the lateral wall of the bladder. |
|
| C67.9 | Malignant neoplasm of bladder, unspecified | Use when the specific site of the bladder tumor is not documented. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutTransitional Cell Carcinoma
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Transitional Cell Carcinoma.
Using outdated terminology 'transitional cell carcinoma'
Impact
Clinical: May lead to confusion in clinical communication., Regulatory: Non-compliance with updated terminology standards., Financial: Potential for claim denials if terminology is not aligned with coding standards.
Mitigation
Use 'urothelial carcinoma' in clinical documentation., Update templates and forms to reflect current terminology.
Using C67.9 when the tumor site is documented
Impact
Reimbursement: May result in lower reimbursement due to lack of specificity., Compliance: Non-compliance with coding guidelines., Data Quality: Decreases accuracy of cancer registry data.
Mitigation
Ensure the specific site is coded, such as C67.2 for lateral wall.
Specificity of tumor site coding
Impact
Audits may focus on whether the specific site of bladder tumors is documented and coded.
Mitigation
Ensure all clinical documentation specifies the tumor site within the bladder.